CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, is focused on developing high-value human therapeutics. Their drug development pipeline includes six programs in clinical development. The Company owns and operates a research and development facility in San Diego, California, and holds a 45% equity interest in RXi Pharmaceuticals (NasdaqCM: RXII ). For further information, visit the Company’s web site at www.cytrx.com.
- 18 years ago
QualityStocks
CytRx Corporation (NASDAQ: CYTR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Why TruGolf Holdings Inc. (NASDAQ: TRUG) Is ‘One to Watch’
TruGolf (NASDAQ: TRUG) is pursuing a strategic expansion into blockchain-based financial infrastructure through its pending…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Brings Interactive Experiences to Major Sports and Entertainment Audiences
Versus Systems (NASDAQ: VS) uses gamification and audience engagement technology to help brands, sports teams,…
-
QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Builds Momentum with Potential 1,500-Home Pipeline
BOXABL (NASDAQ: BXBL) has signed a multiyear purchase agreement with LC Vegas Acquisitions, LLC for…